Immunotherapeutics against cancer and infectious diseases

ISA Pharmaceuticals B.V. is developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.

News

February 15, 2018
ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination
January 3, 2018
ISA Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference 2018

Events

May 14 – 16, 2018
Bio€quity Europe 2018
May 15 – 17, 2018
CIMT Meeting

Latest Publications

September 5, 2016
Cancer Research / Science Translational Medicine
Cancer Research / Science Translational Medicine

More news

More events

More publications

Loading Quotes...